Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients

Cytomegalovirus Infection Clinical Trial

— 2006/25  

Official title:

Cellular Immunity, Cytomegalovirus Infection and Septic Shock in ICU Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00699868
• Other study ID #: 2007-A01197-46
• Status: Completed
• Phase: N/A
• First received: June 13, 2008
• Last updated: June 1, 2012
• Start date: March 2008
• Est. completion date: August 2011

Study information

• Verified date: June 2012
• Source: Assistance Publique Hopitaux De Marseille
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This prospective study evaluate the immune status of patients admitted in ICU.CMV remains dormant in the body, but in people with immune deficiency, CMV could reactivate and cause life-threatening pneumonia.

Description:

Candidates will be screened with medical history and blood tests.Then, 2 groups of 20 patients (with or without CMV reactivation) matched for CMV status will be compared for their immune system against CMV.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: August 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age more than 18-year-old

• Informed consent

Exclusion Criteria:

• minors,

• pregnant or lactating women,

• adults under guardianship,

• immunosuppression at the entrance to resuscitation,

• AIDS

Study Design

Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Cytomegalovirus Infection
• Cytomegalovirus Infections

Intervention

Other:
• Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Sampling of blood
• Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Sampling of blood

Locations

Country	Name	City	State
France	Hôpital de Sainte Marguerite- Service de Réanimation Médicale	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bring to light the quantitative and qualitative immunological modifications of the present cells NK before the arisen of an infection to CMV		24 months	No
Secondary	Bring to light the quantitative and qualitative immunological modifications of cells NK in the consequences of an infectious shock		24 months	No